Human SERPING1 Stable Cell Line - NCI-H520

The SERPING1 gene encodes a C1 inhibitor (C1-INH), a serine protease inhibitor that is a major regulator of the classical complement system pathway, lectin pathway, and contact system (kallikrein-kinin system). Located on chromosome 11 q12.1, C1-INH functions by covalently binding to and inactivating target proteases, including C1r, C1s, MASP-1/2, and plasma kallikrein. This regulation is crucial for preventing excessive bradykinin production and aberrant activation of the complement cascade. Clinically, heterozygous loss-of-function mutations in the SERPING1 gene or the presence of autoantibodies lead to hereditary angioedema (HAE), a life-threatening condition characterized by recurrent, severe swelling of the skin, gastrointestinal tract, and upper respiratory tract. In oncology, SERPING1 has recently been identified as a candidate tumor suppressor gene for various malignancies, including lung adenocarcinoma and prostate cancer.

The stable SERPING1-expressing human cell line in the NCI-H520 context provides a sophisticated model for studying the role of protease regulation in squamous cell lung cancer. NCI-H520 is a mature human lung squamous cell carcinoma line representing a clinically aggressive and often treatment-resistant subtype of non-small cell lung cancer. This cell line provides a platform for stable SERPING1 expression, enabling researchers to quantify how C1-INH secretion affects tumor cell invasion and the in vitro activation of the kallikrein-kinin pathway. This product is of significant value for the pharmaceutical industry in screening novel cancer-associated adverse events (HAEs) and validating the anti-inflammatory effects of C1-INH in the cancer context. The stability of this cell line ensures consistency in the secretion levels of the functional inhibitor. This tool is crucial for researchers working to develop targeted therapies that utilize protease inhibition to overcome tumor-associated inflammation and immune evasion.